Health

Wake Radiology Chief Operating Officer Parul Galloway Receives 2026 Women in Business Award by the Triangle Business Journal

RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Wake Radiology UNC Health Rex is proud to announce that Chief Operating…

2 months ago

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its…

2 months ago

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results

TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company")…

2 months ago

Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year…

2 months ago

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics…

2 months ago

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

2 months ago

MitoSynergy Introduces BioCopper1 – A Clinically Proven Nutraceutical Designed for Mitochondrial Performance

Scottsdale, AZ, March 24, 2026 (GLOBE NEWSWIRE) -- MitoSynergy, a science-driven wellness company focused on cellular and mitochondrial health, today…

2 months ago

BioSyent Announces Grant of Restricted Share Units

March 24, 2026 17:30 ET  | Source: BioSyent Inc. MISSISSAUGA, Ontario, March 24, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”…

2 months ago

Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease…

2 months ago

Idorsia announces the nomination of three candidates for election to the Board of Directors

Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting…

2 months ago